Q: What is Wynzora used for?

Wynzora is used to treat plaque psoriasis .

Q: How does Wynzora work?

How Wynzora Works Wynzora is a combination medication containing calcipotriene and betamethasone dipropionate. Each ingredient targets a different aspect of plaque psoriasis to help clear the skin. Calcipotriene: This ingredient is a synthetic form of vitamin D. In plaque psoriasis, skin cells grow and multiply much faster than normal, which creates thick, scaly patches. Calcipotriene works by slowing down the excessive production of these skin cells, helping the skin return to a more normal growth cycle. Betamethasone dipropionate: This is a potent corticosteroid. It works by suppressing the immune response in the skin to reduce inflammation. This helps relieve the redness, swelling, and itching often experienced with psoriasis plaques. Together, these two components address both the rapid cell turnover and the inflammatory response that characterize the condition.

Q: What are the active ingredients in Wynzora?

The active ingredients in Wynzora are betamethasone and calcipotriene .

Q: What are the side effects of Wynzora?

Common side effects of Wynzora may include: application site irritation itching burning Always consult with a healthcare professional about potential side effects.

Q: What drug class is Wynzora?

Wynzora belongs to the vitamin D analog and corticosteroid combination drug class.

Q: What is the dosage of Wynzora and how do I take it?

How to Apply Wynzora cream should be applied once daily to the affected skin areas. Gently rub the cream into the skin until it is fully absorbed. Wash your hands thoroughly after application, unless you are using the medication to treat your hands. Usage Guidelines Do not use this medication on your face, groin, or underarms. Avoid applying the cream to skin that is thinned, broken, or infected. Do not cover the treated area with bandages, dressings, or wraps unless specifically instructed by a healthcare provider. This medication is typically used for a maximum of eight weeks. Follow your healthcare provider's instructions regarding when to stop treatment and do not use more than the prescribed amount. Missed Dose If you miss a dose, apply it as soon as you remember. If it is almost time for your next scheduled application, skip the missed dose and continue with your regular routine. Do not apply extra cream to make up for a missed dose.

Q: Is Wynzora safe during pregnancy and breastfeeding?

Pregnancy There is limited data regarding the use of Wynzora in pregnant women to determine a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Animal studies involving the systemic administration of the active ingredients, calcipotriene and betamethasone dipropionate, have shown potential for developmental toxicity when given at high doses. However, topical application generally results in lower systemic absorption than oral or injectable forms of these medications. Pregnant individuals should discuss the potential risks and benefits with their healthcare provider before starting treatment. It is generally recommended to use the smallest amount of the medication for the shortest duration possible if treatment is necessary during pregnancy. Breastfeeding It is not known if the active ingredients in Wynzora are present in human milk, or if they affect milk production or the nursing infant. Because many medications can be passed through breast milk, caution is advised when using this product while nursing. To reduce the risk of exposure to a nursing infant, consider the following precautions: Do not apply the cream directly to the breast or nipple area to prevent the infant from accidentally swallowing the medication or coming into direct contact with it. Wash your hands thoroughly after applying the medication if you will be handling your baby. Speak with a healthcare professional to evaluate the risks and benefits of using this medication while breastfeeding.

Q: What forms and strengths does Wynzora come in?

Dosage Forms Wynzora is supplied as a cream for topical application to the skin. It is a combination medication that contains both a vitamin D analog and a corticosteroid. Available Strengths Wynzora cream is available in one strength: Calcipotriene 0.005% and betamethasone dipropionate 0.064%

Q: What is the FDA approval status of Wynzora?

FDA Approval and Indication The U.S. Food and Drug Administration (FDA) approved Wynzora in July 2020. It is indicated for the topical treatment of plaque psoriasis in patients 18 years of age and older. Regulatory Status Wynzora is a fixed-dose combination product containing calcipotriene, which is a vitamin D analog, and betamethasone dipropionate, a corticosteroid. It is classified as a prescription-only medication. There are currently no boxed warnings or Risk Evaluation and Mitigation Strategies (REMS) associated with this drug.

Question 1

What is Wynzora?

Accepted Answer

Wynzora is a medication that contains two active ingredients: calcipotriene, a form of vitamin D that helps control skin cell production, and betamethasone dipropionate, a corticosteroid that helps decrease inflammation.

By combining these two types of medicine, the cream addresses both the rapid cell turnover and the underlying irritation associated with certain skin conditions. This combination therapy works to improve the appearance and texture of the skin.

Question 2

What is Wynzora used for?

Accepted Answer

Wynzora is used to treat plaque psoriasis.

Question 3

How does Wynzora work?

Accepted Answer

How Wynzora Works

Wynzora is a combination medication containing calcipotriene and betamethasone dipropionate. Each ingredient targets a different aspect of plaque psoriasis to help clear the skin.

Calcipotriene: This ingredient is a synthetic form of vitamin D. In plaque psoriasis, skin cells grow and multiply much faster than normal, which creates thick, scaly patches. Calcipotriene works by slowing down the excessive production of these skin cells, helping the skin return to a more normal growth cycle.
Betamethasone dipropionate: This is a potent corticosteroid. It works by suppressing the immune response in the skin to reduce inflammation. This helps relieve the redness, swelling, and itching often experienced with psoriasis plaques.

Together, these two components address both the rapid cell turnover and the inflammatory response that characterize the condition.

Question 4

What are the active ingredients in Wynzora?

Accepted Answer

The active ingredients in Wynzora are betamethasone and calcipotriene.

Question 5

What are the side effects of Wynzora?

Accepted Answer

Common side effects of Wynzora may include:

application site irritation
itching
burning

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Wynzora?

Accepted Answer

Wynzora belongs to the vitamin D analog and corticosteroid combination drug class.

Question 7

What is the dosage of Wynzora and how do I take it?

Accepted Answer

How to Apply

Wynzora cream should be applied once daily to the affected skin areas. Gently rub the cream into the skin until it is fully absorbed. Wash your hands thoroughly after application, unless you are using the medication to treat your hands.

Usage Guidelines

Do not use this medication on your face, groin, or underarms.
Avoid applying the cream to skin that is thinned, broken, or infected.
Do not cover the treated area with bandages, dressings, or wraps unless specifically instructed by a healthcare provider.
This medication is typically used for a maximum of eight weeks. Follow your healthcare provider's instructions regarding when to stop treatment and do not use more than the prescribed amount.

Missed Dose

If you miss a dose, apply it as soon as you remember. If it is almost time for your next scheduled application, skip the missed dose and continue with your regular routine. Do not apply extra cream to make up for a missed dose.

Question 8

Is Wynzora safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

There is limited data regarding the use of Wynzora in pregnant women to determine a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Animal studies involving the systemic administration of the active ingredients, calcipotriene and betamethasone dipropionate, have shown potential for developmental toxicity when given at high doses. However, topical application generally results in lower systemic absorption than oral or injectable forms of these medications.

Pregnant individuals should discuss the potential risks and benefits with their healthcare provider before starting treatment. It is generally recommended to use the smallest amount of the medication for the shortest duration possible if treatment is necessary during pregnancy.

Breastfeeding

It is not known if the active ingredients in Wynzora are present in human milk, or if they affect milk production or the nursing infant. Because many medications can be passed through breast milk, caution is advised when using this product while nursing.

To reduce the risk of exposure to a nursing infant, consider the following precautions:

Do not apply the cream directly to the breast or nipple area to prevent the infant from accidentally swallowing the medication or coming into direct contact with it.
Wash your hands thoroughly after applying the medication if you will be handling your baby.
Speak with a healthcare professional to evaluate the risks and benefits of using this medication while breastfeeding.

Question 9

What forms and strengths does Wynzora come in?

Accepted Answer

Dosage Forms

Wynzora is supplied as a cream for topical application to the skin. It is a combination medication that contains both a vitamin D analog and a corticosteroid.

Available Strengths

Wynzora cream is available in one strength:

Calcipotriene 0.005% and betamethasone dipropionate 0.064%

Question 10

What is the FDA approval status of Wynzora?

Accepted Answer

FDA Approval and Indication

The U.S. Food and Drug Administration (FDA) approved Wynzora in July 2020. It is indicated for the topical treatment of plaque psoriasis in patients 18 years of age and older.

Regulatory Status

Wynzora is a fixed-dose combination product containing calcipotriene, which is a vitamin D analog, and betamethasone dipropionate, a corticosteroid. It is classified as a prescription-only medication. There are currently no boxed warnings or Risk Evaluation and Mitigation Strategies (REMS) associated with this drug.

Question 11

What should I know about Wynzora and cost?

Accepted Answer

Insurance Coverage

The cost of Wynzora varies based on your insurance provider and the specific details of your prescription drug plan. Some plans may require prior authorization before they will cover the medication.

Financial Assistance

Manufacturer savings cards or copay coupons may be available for eligible patients with commercial insurance to help reduce out-of-pocket expenses. Patients without insurance or those with limited coverage may qualify for patient assistance programs based on financial need.

Generic Availability

While the combination of calcipotriene and betamethasone dipropionate is available as a generic in other topical forms, such as ointments or suspensions, Wynzora is a branded cream. Generic medications typically cost less than brand-name drugs, but the specific formulation of Wynzora may be necessary for your condition as determined by a healthcare professional.

Wynzora

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Wynzora

Hospitals.net Disclosure